Abstract：
Objective: We aimed to explore the clinical value of MDS1 and EVI1 complex locus (MECOM) in lung adenocarcinoma (LUAD). Methods: Bioinformatics and experimental validation confirmed MECOM expression levels in LUAD. The value of MECOM was analyzed by receiver operating characteristic (ROC) curve and Cox regression analysis. Results: Serum MECOM levels were lower in LUAD and correlated with gender, TNM stage, tumor size, lymph node metastasis and distant metastasis. The ROC curve showed that the area under the curve of MECOM was 0.804 for LUAD and, of note, could reach 0.889 for advanced LUAD; specificity was up to 90%. Conclusion: MECOM may contribute to independently identifying LUAD patients, particularly in advanced stages.
Lung adenocarcinoma is a common type of lung cancer with a high incidence and death rate. However, clinical indicators that effectively identify lung adenocarcinoma patients are still lacking. The protein encoded by the MECOM gene is a DNA-binding protein regulating gene expression, which has been found to play a cancer-promoting role in many cancers, but we found that it may play a cancer-suppressing role in lung adenocarcinoma. This study aimed to confirm whether MECOM can be a predictor for lung adenocarcinoma. Our results showed that lung adenocarcinoma patients had lower serum MECOM levels than healthy people, and patients with lower MECOM levels had a shorter survival rate. That is, patients with lower serum MECOM levels may indicate a high risk of developing lung adenocarcinoma and death. Thus, the MECOM gene is expected to be a predictor associated with the risk of developing lung adenocarcinoma and death.
Lung adenocarcinoma is a common type of lung cancer with a high incidence and death rate. However, clinical indicators that effectively identify lung adenocarcinoma patients are still lacking. The protein encoded by the MECOM gene is a DNA-binding protein regulating gene expression, which has been found to play a cancer-promoting role in many cancers, but we found that it may play a cancer-suppressing role in lung adenocarcinoma. This study aimed to confirm whether MECOM can be a predictor for lung adenocarcinoma. Our results showed that lung adenocarcinoma patients had lower serum MECOM levels than healthy people, and patients with lower MECOM levels had a shorter survival rate. That is, patients with lower serum MECOM levels may indicate a high risk of developing lung adenocarcinoma and death. Thus, the MECOM gene is expected to be a predictor associated with the risk of developing lung adenocarcinoma and death.
摘要：
目的:探讨MDS1和EVI1复合物位点(MECOM)在肺腺癌(LUAD)中的临床价值。方法：生物信息学和实验验证证实了LUAD中MECOM的表达水平。通过受试者工作特征（ROC）曲线和Cox回归分析分析MECOM值。结果:LUAD患者血清MECOM水平较低,且与性别相关,TNM阶段,肿瘤大小,淋巴结转移和远处转移。ROC曲线显示,LUAD的MECOM曲线下面积为0.804,值得注意的是，晚期LUAD可达到0.889；特异性高达90%。结论:MECOM可能有助于LUAD患者的独立识别,特别是在高级阶段。
肺腺癌是肺癌的一种常见类型，具有很高的发病率和死亡率。然而,目前仍缺乏有效鉴别肺腺癌患者的临床指标。MECOM基因编码的蛋白质是调节基因表达的DNA结合蛋白，已发现在许多癌症中发挥促癌作用，但是我们发现它可能在肺腺癌中起抑癌作用。本研究旨在证实MECOM是否可以作为肺腺癌的预测因子。我们的结果表明，肺腺癌患者的血清MECOM水平低于健康人，MECOM水平较低的患者生存率较短。也就是说,血清MECOM水平较低的患者可能提示发生肺腺癌和死亡的风险较高.因此，MECOM基因有望成为与肺腺癌和死亡风险相关的预测因子.
肺腺癌是肺癌的一种常见类型，具有很高的发病率和死亡率。然而,目前仍缺乏有效鉴别肺腺癌患者的临床指标。MECOM基因编码的蛋白质是调节基因表达的DNA结合蛋白，已发现在许多癌症中发挥促癌作用，但是我们发现它可能在肺腺癌中起抑癌作用。本研究旨在证实MECOM是否可以作为肺腺癌的预测因子。我们的结果表明，肺腺癌患者的血清MECOM水平低于健康人，MECOM水平较低的患者生存率较短。也就是说,血清MECOM水平较低的患者可能提示发生肺腺癌和死亡的风险较高.因此，MECOM基因有望成为与肺腺癌和死亡风险相关的预测因子.
